179 related articles for article (PubMed ID: 21926376)
1. Re: an empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
Vickers AJ
J Natl Cancer Inst; 2011 Nov; 103(21):1635-6. PubMed ID: 21926376
[No Abstract] [Full Text] [Related]
2. Re: an empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
Loeb S; Metter EJ; Carter HB
J Natl Cancer Inst; 2011 Nov; 103(21):1636-7; author reply 1637. PubMed ID: 21926375
[No Abstract] [Full Text] [Related]
3. Measuring the importance of PSA velocity.
Tuma RS
J Natl Cancer Inst; 2011 Mar; 103(6):454-61. PubMed ID: 21393606
[No Abstract] [Full Text] [Related]
4. Conflicting clinical guidelines.
Schmidt C
J Natl Cancer Inst; 2013 Jan; 105(1):2-3. PubMed ID: 23257157
[No Abstract] [Full Text] [Related]
5. [Standards for the punch biopsy of the prostate].
Seitz M; Schlenker B; Gratzke C; Weidlich P; Stief CG; Reich O
MMW Fortschr Med; 2007 Jan; 149(4):35-6. PubMed ID: 17615715
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen screening in prostate cancer: perspectives on the evidence.
Wilt TJ; Scardino PT; Carlsson SV; Basch E
J Natl Cancer Inst; 2014 Mar; 106(3):dju010. PubMed ID: 24594482
[No Abstract] [Full Text] [Related]
7. [Screening and prevention of prostate cancer].
Roosen A
MMW Fortschr Med; 2010 May; 152(19):37-9. PubMed ID: 20557000
[No Abstract] [Full Text] [Related]
8. Serum prostate-specific antigen for prostate cancer early detection: total, free, age- stratified, or complexed?
Carroll PR
Urology; 2001 Apr; 57(4):591-3. PubMed ID: 11306354
[No Abstract] [Full Text] [Related]
9. Re: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves.
Jacobsen SJ; Guess HA; Oesterling JE
J Urol; 1996 Apr; 155(4):1395-6. PubMed ID: 8632594
[No Abstract] [Full Text] [Related]
10. PSA and the detection of prostate cancer.
Robbins AS
JAMA; 1994 Jan; 271(3):192-3. PubMed ID: 7506314
[No Abstract] [Full Text] [Related]
11. Don't test -- don't treat: the new paradigm for the treatment of prostate cancer?
Albani JM
Mo Med; 2011; 108(6):409-12. PubMed ID: 22338731
[No Abstract] [Full Text] [Related]
12. Re: The Value of Magnetic Resonance Imaging in the Detection of Prostate Cancer in Patients with Previous Negative Biopsies and Elevated Prostate-Specific Antigen Levels: A Meta-Analysis.
Siegel C
J Urol; 2015 Aug; 194(2):395. PubMed ID: 26195367
[No Abstract] [Full Text] [Related]
13. Prostate-specific antigen velocity is not better than total prostate-specific antigen in predicting prostate biopsy diagnosis.
Gorday W; Sadrzadeh H; de Koning L; Naugler CT
Clin Biochem; 2015 Dec; 48(18):1230-4. PubMed ID: 26164541
[TBL] [Abstract][Full Text] [Related]
14. [Prostate cancer screening: no proof of the benefit].
Laplanche A; Hill C
Presse Med; 2009 Oct; 38(10):1393-5. PubMed ID: 19647979
[No Abstract] [Full Text] [Related]
15. Numbers needed to decide.
Woloshin S; Schwartz LM
J Natl Cancer Inst; 2009 Sep; 101(17):1163-5. PubMed ID: 19671771
[No Abstract] [Full Text] [Related]
16. Early-stage prostate cancer, PSA screening rates decline.
Printz C
Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
[No Abstract] [Full Text] [Related]
17. A rational basis for chemoprevention of prostate cancer.
Huang CJ; Baum ML
Am J Bioeth; 2011 Dec; 11(12):27-9. PubMed ID: 22146027
[No Abstract] [Full Text] [Related]
18. [Comment on Grond, A., M. Ostermann-Myrau: Benign and malignant diseases of the prostate].
Grond A
Versicherungsmedizin; 1995 Apr; 47(2):66-7. PubMed ID: 7539193
[No Abstract] [Full Text] [Related]
19. PSA test not recommended by Canadian Task Force.
Tanday S
Lancet Oncol; 2014 Dec; 15(13):e589. PubMed ID: 25499287
[No Abstract] [Full Text] [Related]
20. [Implementation of guidelines for PSA testing in general practice].
Jodal HC; Reyes YD; Roksund G; Bretthauer M
Tidsskr Nor Laegeforen; 2014 Nov; 134(21):2032-4. PubMed ID: 25387926
[No Abstract] [Full Text] [Related]
[Next] [New Search]
